285 results about "Doxycycline" patented technology

The present invention generally relates to a method for developing, generating and selecting tumor-free embryonic stem (ES)-like pluripotent cells using electroporation delivery of an inducible tumor suppressor mir-302 agent into mammalian cells. More particularly, the present invention relates to a method and composition for generating a Tet-On / Off recombinant transgene capable of expressing a manually re-designed mir-302 microRNA (miRNA) / shRNA agent under the control of doxycyclin (Dox) in human somatic / cancer cells and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state.

This invention relates to antimicrobial wound dressings having a non-leaching antimicrobial activity, releasable antimicrobial and antiprotease agents, and a controlled-release bioactive agent such as doxycycline. The Wound dressing material is absorbent and acts as a substrate for antimicrobial and antiprotease agents as well as bioactive agents. More generally, this invention relates to methods and compositions for materials having a non-leaching coating that has antimicrobial properties. The coating is applied to substrates such as gauze-type wound dressings, powders and other substrates. Covalent, non-leaching, non-hydrolyzable bonds are formed between the substrate and the polymer molecules that form the coating. A high concentration of anti-microbial groups on multi-length polymeric molecules and relatively long average chain lengths, contribute to an absorbent or superabsorbent surface with a high level antimicrobial efficacy. Utilization of non-leaching coatings having a plurality of anionic or cationic sites is used according to this invention to bind a plurality of oppositely charged biologically or chemically active compounds, and to release the bound oppositely charged biologically or chemically active compounds from said substrate over a period of time to achieve desired objectives as diverse as improved wound healing to reduction in body odor.

The present invention relates to the construction of a TRAIL DNA cassette for the production of a secretable trimeric rTRAIL, the development of pCMVdw vectors and pAAVdw vectors harboring a feed-forward amplification loop type Tet-On system that can be packaged into AAV particles, the preparation of a recombinant vectors by the combination of the TRAIL DNA cassette and the two vectors, and the treatment of diseases including cancer using such vectors. The present invention provides a TRAIL DNA cassette comprising a secretion signal (SS) sequence, a trimer-forming domain (TFD) and a TRAIL(114-281) coding cDNA. The TRAIL cassette thus constructed can be cloned into an appropriate expression vector, and subsequently used in the mass production of a secretable recombinant trimeric TRAIL protein or administered to a patient for a gene therapy.

This invention relates to an oral dosage form of a pharmaceutically active ingredient comprising: (a) an outer capsule and (b) non-uniform pellets, having a non-uniform shape and / or size, contained within the capsule, wherein the pellets comprise a compressed powder comprising a pharmaceutically active ingredient. In one embodiment the active ingredient is selected from the group consisting of doxycycline, omeprazole, esomeprazole, and propafenone. Pharmaceutical formulations of the active ingredients as well as methods and tools for making the oral dosage form are also described.

The present invention is directed to a pharmaceutical composition comprising a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. A suitable antibiotic is selected from the group consisting of doxycycline, gentamicin, tobramicin, ciprofloxacin, clindamycin, clarithromycin, azithromycin and metronidazole. Preferred antibiotics are doxycycline and ciprofloxacin. More preferably, the antibiotic is doxycycline. In its second aspect, the present invention is directed to a method for treating periodontal disease in a mammalian patient comprising administering to a mammalian patient in need of such treatment a therapeutically effective amount of misoprostol and an effective amount of an antibiotic. Typically, the mammalian patient is a human.

The present invention is a solid dosage form of a doxycycline metal complex. The present invention also includes a process for making a doxycycline metal complex in a solid dosage form. The process comprises the steps of (i) providing an aqueous solution of doxycycline or a physiologically acceptable salt thereof; (ii) admixing a metal salt with the aqueous solution; (iii) admixing a base to increase the pH of the aqueous solution, thereby forming a suspension of doxycycline metal; and (iv) drying the suspension, thereby forming a dry granulation of doxycycline metal complex.

The present invention provides a panel of transcriptional activator fusion proteins which comprises both tetracycline controlled transactivator proteins and reverse tetracycline transactivator proteins. These transactivators have novel phenotypes such as altered basal transcriptional activity in the absence of doxycycline, altered induced transcriptional activity in the presence of doxycycline, or differential induction by tetracycline and analogs of tetracycline.

The present invention relates to a method for determining 10 kinds of antibiotics in a water environment through combination of a sample pre-treatment technology and HPLC-MS, and belongs to the field of detection of safety of trace organic contaminant residue in the water environment. The method is characterized in that a water sample is separated and enriched through combination of solid phase extraction and dispersive liquid-liquid microextraction (SPE-DLLME), and then an ultra-high performance liquid chromatography-mass spectrometry instrument (UPLC-MS / MS) is adopted as a detection tool to directly determine the contents of 10 kinds of common antibiotics in the water environment (drinking water, tap water, river water, sewage treatment plant influent and effluent), wherein the 10 kinds of the common antibiotics respectively are sulfadiazine, sulfamethoxazole, oxytetracycline, tetracycline, doxycycline, ciprofloxacin, levofloxacin, chloramphenicol, cefuroxime axetil and tinidazole. According to the present invention, the water sample pre-treatment method and the instrument detection conditions are investigated and optimized, and the optimal SPE-DLLME-UPLC-MS / MS method is established and is successfully applied for the real sample determination; and compared with the traditional method, the method of the present invention has advantages of high sensitivity, high extraction recovery rate, wide application objects, environmental protection, and the like.

The present invention relates, at least in part, to the use of substituted tetracycline compounds for regulation of expression of nucleic acids operably linked to a tetracycline operator system. The invention pertains to compounds used in a regulatory system which utilizes components of the Tet repressor / operator / inducer system of prokaryotes to regulate gene expression in cells. Use of certain substituted tetracycline compounds, as featured in the methods of the invention, result in improved dose-response results when compared to those for e.g., tetracycline and doxycycline. Certain methods of the invention thus allow for enhanced control of the Tet repressor / operator / inducer system in regulating gene expression in cells.

A compound florfenicol injection for treating the pneumonia and bacterial lung infection of pig is prepared from florfenicol, doxycycline, dimethyl formamide, magnesium dichloride, polyvinyl pyrrolidone, trimethoprim and propanediol. Its preparing process is also disclosed.

A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described.

The invention discloses an application of a Pd catalyst in a hydrogenation process for producing doxycycline, belonging to the field of pharmaceutical chemistry synthesis. The method is as follows: based on polyvinyl chloride-polyethylene polyamine-loaded palladium complex (pvc-pp-Pd) used as a catalyst, and 11 alpha-chlorine-6-methylene oxytetracycline or 11 alpha-chlorine-6,12-hemiketal oxytetracycline or metacycline or salts thereof used as raw material, introducing hydrogen, stirring and reacting, filtering, adding sulfo-group salicylic acid to filtrate so as to form salt; and cooling, filtering, washing and drying so as to obtain alpha-6-deoxytetracycline sulfo-group salicylic acid salt, wherein the yield is higher than 90%, the content of the corresponding beta-6-deoxytetracycline sulfo-group salicylic acid salt isomer is less than 1%. The method has the advantages of mild reaction conditions, good reaction directionality and less side reactions; a toxic agent is not required inthe hydrogenation process, and pollutant emission is reduced, thereby being beneficial to protecting the environment; and the catalyst can be recycled, and production cost is reduced, thereby extremely being beneficial to industrial production.

The present invention relates to a method for treating a fatty liver disease or disorder in a patient in need thereof. The method comprises administering at least one matrix metalloproteinase (“MMP”) inhibitor to the patient. Fatty liver disease or disorders include, for example, NAFLD, NASH, ALD, fatty liver associated with chronic hepatitis infection, TPN, steroid treatment, tamoxifen treatment, gastrointestional operations, diabetes and Reye's Syndrome. The method is particularly useful when the fatty liver disease is associated with TPN and the patient is an infant or when the patient is obese. MMP inhibitors useful in the present invention include, for example, Marimastat, tetracyclines, Prinomastat, Batimastat, BAY 12-9566, AG3340, BMS-275291, Neovastat, BB-3644, KB-R7785, TIMP1, TIMP2, doxycycline, minocycline, RS-130,830; CGS 27023A, Solimastat, Ro 32-3555, BMS-272591, and D2163. Marimastat is a preferred MMP inhibitor.

The invention discloses a preparation method and application of a nano fiber molecularly-imprinted polymer. The preparation method is characterized by comprising the following steps: carrying out silanization treatment and denaturation on nano fiber, and synthesizing the nano cellulose molecularly-imprinted polymer by using doxycycline as template molecules, acetonitrile / methanol as a pore-forming agent, methacrylic acid as a functional monomer, trimethylolpropane trimethyl acrylate as a crosslinking agent and azodiisobutyronitrile as an initiator. The application method comprises the following steps: characterizing the synthesized polymer material, filling in a solid-phase extraction column, and determining the concentration of tetracycline antibiotics in the sample to be detected according to the standard curve in combination with high-performance liquid chromatography. The application method has the advantages of high sensitivity, high detection speed, low detection limit, high efficiency and low price.

The invention relates to the technical field of environment detection and is suitable for measuring erythrocin, chloramphenicol, sulfamethoxazole, sulfadiazine, roxithromycin, cefotiam, pyridazol, norfloxacin, ofloxacin, tetracycline and doxycycline in sewage, surface water and bottom mud. After being sampled, a water sample and a mud sample are pretreated and detected through ultra-high performance liquid chromatography-triple quadrupole mass spectrometry, and qualitative diagnosis is conducted through the characteristic ion pair (m / z) of a target compound, a standard curve is drawn accordingto the response value and the corresponding concentration, and the external standard method is used in quantification, so that the contents of various antibiotics in the sample are obtained. The method is accurate, sensitive and simple, and is suitable for measuring the contents of 11 typical antibiotics in the sewage, the surface water and the mud at the same time.

A veterinary medicine for preventing and treating the frequently encountered diseases of pig, such as metritis, mammitis, acyesis, sterility, dysentery, epidemic enteritis, paratyphoid, asthma, etc is prepared from 15 raw materials including florfenicol, amoxicillin, lucomycin, doxycycline, etc.

The invention relates to a preparation method of injectable nano-short fibers loaded with an anti-cancer medicine. The preparation method comprises the following steps: loading the anti-cancer medicine DOX (Doxycycline) on MWNTs (multi-walled carbon nanotubes) with a hollow structure to obtain MWNTs powder loaded with the DOX; carrying out electrostatic spinning on the MWNTs powder loaded with the DOX and biodegradable macromolecular PLGA (poly(lactic-co-glycolic acid)) under a specific condition to obtain a compound nano-fiber membrane; finally, carrying out crushing and homogenization treatment on the compound nano-fiber membrane to prepare the injectable nano-short fibers loaded with the anti-cancer medicine. The injectable nano-short fibers loaded with the anti-cancer medicine have a good releasing performance, can be used for injecting, has high medicine utilization rate and high stability and can be used for more accurately, effectively and safely treating tumor parts; the injectable nano-short fibers loaded with the anti-cancer medicine have good blood compatibility and cell compatibility, can be used for killing cancer cells and do not cause injuries to normal tissue cells of human bodies; the injectable nano-short fibers can emit two types of fluorescent light, are swallowed by human body cells and can be used for researching a cancer cell treatment mechanism.

The invention provides an aptamer nucleic acid probe kit for detecting doxycycline residue as well as a preparation method and application thereof. A nanometer magnetic sphere is an inner core and the outer surface of the nanometer magnetic sphere is bonded with a doxycycline nucleic acid aptamer chain, wherein the doxycycline nucleic acid aptamer chain is 5'-GCATGCCTTAAGCGATCG-N35-CCATATTATAAGGCATGC-3', N represents any one of A, T, C and G, N35 represents that random fragment length comprises 35 basic groups, and the probe is suitable for detection of doxycycline residue in animal body.

Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.

The invention provides a novel high throughput screening model for hepatitis C virus (HCV) resistant drugs. The high throughput screening model can be applied to research and drug screening of human HCV infection mechanisms, and is a reporting system carrying out efficient response aiming at HCV infection. After the HCV invades cells, protease NS3 / 4A expressed by the HCV is about to cut and release a tetracycline-regulated transactivator (rtTA) anchored on a mitochondrial outer membrane by an MAVS (mitochondrial antiviral signaling) protein, expression of a reporter gene is activated in the presence of doxycycline or tetracycline, and obvious fluorescence signals are observed in a certain time; or cell death is caused in the presence of GCV (gancilovir). The system is simple to operate, has short experimental period, high efficiency and strong stability, can be widely applied to real-time quantitative observation of HCV infection, flow cell sorting, high throughput compound screening, high throughput host cell target gene screening and molecular mechanism research of HCV infection.

The invention discloses a chemically modified electrode for sensitive detection of doxycycline as well as a preparation method and application thereof. The modified electrode is a glassy carbon electrode with high electrical activity and modified by ZnIn2S4@In2O3@MXene nanocomposite. The invention relates to the field of electroanalytical chemistry and electrochemical sensors. The ZnIn2S4@In2O3@MXene graded tubular heterojunction nanocomposite disclosed by the invention has large specific surface area and high catalytic activity and can increase the enrichment amount of doxycycline in an electrochemical detection medium and improve the measurement sensitivity while effectively accelerating electron transfer and improve the electrochemical response signal; and the composite has the advantages of high selectivity, simplicity and convenience, low price and high stability and is suitable for field detection. The chemically modified electrode prepared by the invention is already successfully applied to the accurate detection of doxycycline in animal-derived food.

The invention belongs to the technical field of detection of biological immunological methods, and particularly relates to a doxycycline detection kit and a preparation method thereof. The kit comprises a sample pad (1), a colloidal gold pad (2), a nitrocellulose membrane (3), a sample suction pad (4) and a poly vinyl chloride (PVC) support plate (5); the colloidal gold pad is anti-doxycycline colloidal gold labeled monoclonal antibody glass fiber (or non-woven fabric); and a doxycycline coupling antigen serving as a detection line (T line) and a goat-anti-mouse antibody IgG serving as a quality control line (C line) are sequentially coated on the nitrocellulose membrane. The doxycycline detection kit is prepared by adopting a colloidal gold immunochromatography assay technology; and the preparation method is simple, can be used for detecting the doxycycline probably existing in a sample, and has the characteristics of convenience in use, simplicity in operation, rapid reaction, economy, practicality and the like.

The invention discloses a doxycycline eyedrop preparation and a preparation method thereof. The doxycycline eyedrop preparation comprises 0.03 to 0.5 wt percent of doxycycline, distilled water, hydroxypropyl-beta-cyclodextrin and an antioxidant and has a pH value of 5.0 to 6.0, wherein the weight ratio of doxycycline to hydroxypropyl-beta-cyclodextrin is 1: (1 to 50). The doxycycline eyedrop preparation can improve the dissolubility, the dissolving rate and the stability of doxycycline medicines.

The invention relates to a composite microbial agent and a preparation method and application thereof, and belongs to the technical field of organic waste treatment. The preparation method of the composite microbial agent comprises the steps of activating first degrading bacteria and second degrading bacteria, and preparing multiple beef extract-peptone solid mediums; inoculating activated degrading bacteria into different beef extract-peptone solid mediums for cultivation according to the type of the contained strain separately, and selecting the first degrading bacteria and the second degrading bacteria in a log phase or a stable phase for dilution separately to obtain first bacterial suspension and second bacterial suspension; and mixing the first bacterial suspension and the second bacterial suspension to obtain the composite microbial agent, wherein the first degrading bacteria comprise bacillus and streptococcus, and the second degrading bacteria comprise pseudomonas, acidophile and acinetobacter. The preparation method is simple and easy to operate and short in consumed time. The composite microbial agent obtained through the method is used for treating organic wastes, and has efficient and stable degradation capacity on oxytetracycline, tetracycline, aureomycin and doxycycline contained in the organic wastes.

The invention relates to a preparation method for a nano SiO2-based doxycycline molecularly imprinted polymer. A doxycycline (DOC) molecularly imprinted polymer with nano silica (nano-SiO2) removed is obtained by using nano-SiO2 as a carrier and DOC as a template molecule, alpha-methylacrylic acid (MAA), ethylene glycol dimethacrylate (EDMA) and 2,2'-azodiisobutyronitrile (AIBN) as functional monomers, a cross-linking agent and an initiator respectively; N,N-dimethylformamide (DMF) as a solvent and through the steps of dissolution, polymerization, SiO2 removal with hydrofluoric acid (HF) and elution. The imprinted polymer is used as a filler for a solid phase extraction column; the obtained solid phase extraction column has good recognizability for the template molecule (DOC) and three template molecule analogues such as tetracycline (TC), oxytetracycline (OTC) and chlortetracycline (CTC); an adsorption rate for DOC can reach 90.2%; an adsorption rate for TC can reach 85.4%; an adsorption rate for OTC can reach 83.7% and an adsorption rate for CTC can reach 86.1%. Therefore, the imprinted polymer can be used for sample pretreatment for residue detections of tetracycline antibiotics in animal derived foods.

Therapeutic composition and method for treating or preventing various conditions and diseases, including inflammatory conditions, allergies, particularly seasonal allergies, and the common cold. In a preferred embodiment, the therapeutic composition is a formulation comprising an antibiotic, preferably a tetracycline, most preferably doxycycline, which has not been chemically modified to eliminate antimicrobial efficacy. The antibiotic is preferably in a vehicle to form a salve or paste for topical application to the skin or the nasal cavity. The therapeutic composition most preferably is a self-applied formulation that consists essentially of a tetracycline, most preferably doxycycline, which has not been chemically modified to eliminate antimicrobial efficacy, and a vehicle such as boric acid, zinc oxide or petroleum jelly.

The invention discloses an application of a combination of a tetracycline medicine and fluconazole (FLC) in the preparation of an antifungal product, and the product thereof, and concretely discloses a synergistic effect of three cell calcium regulators of a non-selective calcium channel retarding agent benidipine (BEN), a selective L-type calcium channel retarding agent nifedipine (NIF) and a calcium ion chelating agent ethylene diamine tetraacetic acid (EDTA) to the FLC and tetracycline antifungal medicines of doxycycline (DOX) and minocycline (MINO), and an application of the three cell calcium regulators in Candida albicans resisting, wherein a synergistic antifungal effect can be generated by the combined application of the FLC, the DOX and the MINO. Results confirm that the combined application of the FLC and the DOX / MINO can generate the synergistic antifungal effect, and has a substantial killing effect on drug-resistant Candida albicans; the BEN, the NIF and the EDTA can obviously enhance the combined antifungal effect of the FLC and the DOX / MINO to the Candida albicans, and can obviously reduce the lowest effective concentration during the combined application of the FLC, the MINO and the DOX; and the combined application of the three calcium regulators and the FLC can enhance the antifungal effect.

The invention discloses a method for recycling sulfosalicylic acid from doxycycline production waste liquid and belongs to the field of medicinal chemistry separation and purification. The method includes the following steps that alkali is added to doxycycline production waste liquid, the alkali reacts with sulfosalicylic acid in the doxycycline production waste liquid, sulfosalicylic acid sodium salt is formed, then ethyl alcohol is recycled, crystallization is conducted, and sodium sulfosalicylate is obtained; the recycled sulfosalicylic acid sodium salt is added to an alcohol solution and an acid solution, after a reaction is ended, filtering is conducted, sodium chloride is removed, filter liquor is concentrated, solvent is recycled, crystallization is conducted, sulfosalicylic acid is obtained, the recycling rate reaches 80% or more, and a product is acceptable in quality. Compared with a traditional recycling process, the sulfosalicylic acid is recycled from the doxycycline production waste liquid, emission of pollutants is reduced, environmental protection is facilitated, the sulfosalicylic acid can be recycled, the production cost is lowered, and the economic and social benefits of doxycycline are raised.

The invention relates to a compound adsorbent based on hippophae rhamnoides linn branches and trunks. The compound adsorbent is produced by the following steps: preparing hippophae rhamnoides linn charcoal by the hippophae rhamnoides linn branches and trunks, and loading nano Fe3O4 grains. The invention further provides a preparation method of the compound adsorbent. The national resource quantity of the hippophae rhamnoides linn branches and trunks is great; and the compound adsorbent is prepared by taking waste biological resources of the hippophae rhamnoides linn branches and trunks as raw materials so that the industrial chain of utilizing the hippophae rhamnoides linn branches and trunks is effectively lengthened. The obtained compound adsorbent can be used for treating doxycycline organic pollutant wastewater and can be regenerated.